drugset / Trial / NCT00239304

Gefitinib (Iressa) in Combo With Chemoradiation in Patients With Locally Advanced Head & Neck Cancer

NCT00239304

Phase 1/2 Completed 40 enrolled AstraZeneca
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To determine the safety and tolerability of gefitinib in combination with cisplatin and radiation (3D-CRT or IMRT) in patients with locally advanced head and neck cancer.

Timeline

Start
2003-06
Primary completion
Completion
2006-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Gefitinib Small molecule
Background Cisplatin Other / unclassified